

Research in Your Backyard

Developing Cures, Creating Jobs



PHARMACEUTICAL
CLINICAL TRIALS IN
FLORIDA

Executive Summary

Clinical Trials in Florida

- Biopharmaceutical research companies are conducting or have conducted more than 7,800 clinical trials of new medicines in collaboration with the state's university medical schools, clinical research centers, and hospitals (1999 to present).
- Of the more than 7,800 clinical trials, 3,840 target the nation's six most debilitating chronic diseases—asthma, cancer, diabetes, heart disease, mental illnesses and stroke.

Economic Benefits of Clinical Trials in Florida

- Biopharmaceutical research companies have been a source of jobs, tax revenue and research spending in Florida.
- A study by Battelle Technology Partnership Practice found that in 2011 the industry supported nearly 84,000 jobs throughout the state.
- Wages and benefits for employees working directly for the biopharmaceutical sector resulted in about \$270 million in federal taxation and \$6.1 million in state taxes.
- Biopharmaceutical research companies generated \$16 billion in goods and services in the state, including the direct economic output of the sector itself, the output of the sector's vendors and

“With such facilities as M.D. Anderson Cancer Center Orlando, the Cleveland Clinic Florida, the University of Miami and the University of Florida, it’s not at all surprising that biopharmaceutical research companies have taken advantage of the state’s strong biopharmaceutical and life sciences infrastructure to conduct nearly 8,000 clinical trials of new medicines in Florida since 1999, including 3,840 for the most debilitating chronic diseases—cancer, diabetes, heart disease, stroke, asthma and mental illnesses.”

—Austin Curry
Executive Director
Elder Care Advocacy of Florida

suppliers and the output generated by the buying power of its workforce.

- Company employees in Florida include life sciences researchers, management executives, office and administrative support workers, production workers, engineers, architects, computer and math experts and sales representatives. Biopharmaceutical companies also supported the jobs of their vendors and suppliers, including construction and IT firms. And the employees of biopharmaceutical companies help to support local restaurants, day care centers and other community businesses.

“Almost 700 of the state’s chronic disease medicine clinical trials are still active and either are about to start recruiting patients or they already are soliciting volunteers. That’s potentially important for patients still seeking the treatments that are best for them—a trial of a new medication could be a good therapeutic option to discuss with doctors. Three of the most debilitating diseases in Florida are cancer, diabetes and heart disease and for those ailments alone, there are 563 trials of new medicines active and recruiting patients in Florida.”

—Pam Langford
President
HEALS of the South

About Clinical Trials

- In the development of new medicines, clinical trials are conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug Administration (FDA) to approve treatments.
- Clinical tests of new drugs are conducted in three phases and account for an average of seven of the 10 to 15 years it takes to bring a new drug from development to patients.
- Clinical trials for a given drug or treatment involve thousands of volunteer patient participants, and the generation of tens of thousands of pages of technical and scientific data.
- Clinical trials are responsible for 45 to 75 percent of the \$1.2 billion average cost of developing one new cutting-edge biotechnology medicine.
- For patients, the trials offer another potential therapeutic option. Clinical tests may provide a new avenue of care for some chronic disease sufferers who are still searching for the medicines that are best for them.
- Some trials are conducted to compare existing treatments while others are done to learn if a drug is appropriate for a particular patient population, such as children. Still others are conducted to find ways to make existing approved drugs more effective and easier to use with fewer side effects.
- All clinical trials must be reviewed and approved by an Institutional Review Board (IRB), an independent committee of physicians, statisticians, local community advocates and others to ensure a trial is ethically conducted and patient rights are protected.
- Clinical trial progress reports must be submitted at least annually to the FDA and IRB.
- All facilities that conduct or support biomedical research involving patients must comply with federal regulations and have an IRB.

Clinical Trials in Florida since 1999—Completed and Active

All Clinical Trials	Six Major Chronic Diseases
7,845	3,840

Source: www.clinicaltrials.gov

Note: Search criteria = Florida, United States; Phase 0, 1, 2, 3; industry only. Search performed 8/31/2013.

Clinical Trials in Florida Communities						
Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Boca Raton	1	21	5	2	4	1
Boynton Beach	—	26	3	4	1	2
Clearwater	1	3	10	13	—	6
Daytona Beach	1	6	4	12	—	6
Fort Lauderdale	1	17	—	5	11	3
Fort Myers	—	56	—	2	11	2
Gainesville	1	22	2	10	12	2
Jacksonville	2	63	19	28	25	10
Melbourne	—	1	5	—	2	2
Miami	12	89	95	28	53	14
Orlando	1	71	16	13	48	3
Pensacola	1	9	2	3	—	—
Sarasota	3	30	1	7	5	7
St. Petersburg	—	44	7	8	9	5
Tallahassee	4	—	2	6	—	3
Tampa	4	164	12	16	22	7
West Palm Beach	—	17	4	2	16	2

Source: www.clinicaltrials.gov

Note: Search criteria = Florida, United States; Phase 0, 1, 2, 3; industry only. Search performed 8/31/2013. See Appendix for detailed information about these clinical trials.

Disease columns will not match totals in the Appendix because some clinical trials are recruiting in more than one city. This list of cities and towns is representative and not a complete list of where clinical trials are taking place in Florida.

“Florida has a good research infrastructure in all parts of the state. Clinical trials are being conducted in at least 17 communities, including Miami, Tampa, Boca Raton, Clearwater, Gainesville, Ft. Myers, Melbourne, Pensacola, Orlando and Jacksonville. These trials give talented local scientists the opportunity to be engaged in cutting-edge biopharmaceutical science as biopharmaceutical companies seek to develop safer and more effective medicines.”

—Julio Fuentes
President
Florida State Hispanic Chamber

Clinical Trials and Chronic Diseases

- Chronic diseases pose the greatest threats to our nation’s health and our ability to treat and prevent medical conditions.
- According to the U.S. Centers for Disease Control and Prevention (CDC), today, in the United States:
 - > Patients with chronic diseases **account for 75 cents of every dollar** spent on health care.
 - > Chronic diseases are the **leading cause of death and disability**.
 - > Chronic diseases are a **leading driver of rising health care costs** with expenses totaling billions of dollars every year.
- Biopharmaceutical research companies are developing new medicines to help treat those conditions that are taking an unprecedented toll on American lives, and many of these medicines are being tested today in clinical trials throughout Florida.
- Since 1999, biopharmaceutical research companies are sponsoring or have sponsored 3,840 clinical

trials of potential new medicines in Florida alone for **asthma, cancer, heart disease, stroke, diabetes and mental illnesses**. Of these trials, 696 are either not yet recruiting or are just now seeking Florida patients. The 696 trials are being conducted at more than 2,000 sites in Florida.

- Biopharmaceutical companies are collaborating on tests with prominent institutions like Nemours Children’s Hospital, the H. Lee Moffitt Cancer Center and Research Institute, M.D. Anderson Cancer Center Orlando, the University of Miami, the University of Florida, Mayo Clinic Florida, Florida Hospital Orlando, Cleveland Clinic Florida and the Mount Sinai Medical Center.
- Some of the medicines being clinically tested in Florida are new-generation biotechnology treatments.

Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	120	19
Cancer	1,953	440
Diabetes	635	76
Heart Disease	287	47
Mental Illness	784	98
Stroke	61	16
Total	3,840	696

Source: www.clinicaltrials.gov

Note: Search criteria = Florida, United States; Phase 0, 1, 2, 3; industry only. Search performed 8/31/2013. **Some clinical trials appear in more than one disease category.**

Clinical Trials in Florida

Clinical tests of new medicines are a vitally important part of the drug development and approval process—they account for 45 to 75 percent of the \$1.2 billion average cost of developing a new drug and are conducted to determine the safety and effectiveness of that treatment in patients.

Some trials are conducted to compare existing treatments and some are done to explore whether a drug is appropriate for a different patient population, such as children. Still others are conducted to find ways to make existing approved drugs more effective and easier to use with fewer side effects.

It is essential that trials be conducted properly so that clinicians and drug reviewers can develop accurate assessments of the efficacy and safety of medicines when used by patients. The FDA is a vigilant regulatory agency and its pharmaceutical review officers are effective in detecting flawed information.

Questionable or confusing data can lead to lengthy delays in product approval or outright FDA rejection of a new drug.

Biopharmaceutical research companies are looking for the best physicians and research institutions to meticulously help design and conduct their clinical trials to determine whether a medicine is safe and effective. Side effects must be painstakingly documented and a determination made as to whether they occur too often and are dangerous.

Clinical tests involve three phases, thousands of volunteer patients, and are often conducted at multiple sites around the country. In Florida, biopharmaceutical companies

Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	120	19
Cancer	1,953	440
Diabetes	635	76
Heart Disease	287	47
Mental Illness	784	98
Stroke	61	16
Total	3,840	696

Source: www.clinicaltrials.gov

Note: Search criteria = Florida, United States; Phase 0, 1, 2, 3; industry only. Search performed 8/31/2013. **Some clinical trials appear in more than one disease category.**

are providing funds to have trials conducted at the states' well-respected medical schools, hospitals and clinical research organizations. According to *U.S. News and World Report*, the **University of Florida** ranked 45th, the **University of Miami** ranked 51st and the **University of South Florida** ranked 80th among this year's top 100 research-oriented medical schools in the United States. Other top research-oriented medical schools in Florida are **Florida State University** and **Nova Southeastern University**.

Asthma is a debilitating condition for more than 25 million Americans, including 7.1 million children under the age of 18. The toll is also severe in Florida, with 1 out of 5 school-age children and 1 out of 12 adults suffering from asthma, according to the Florida Department of Health.

Currently, 19 clinical trials of new asthma medicines are recruiting patients in Florida. Trials are being conducted at the **Nemours Children's Clinic** in Jacksonville and at sites across the state including Miami, Daytona Beach, Tallahassee and Tampa.

Cancer, the second leading cause of death in the United States, now afflicts nearly 14 million Americans, according to the National Cancer Institute. In Florida, more than 118,000 new cancer cases will be diagnosed this year and 42,370 victims in the state will die, according to the American Cancer Society.

Currently, 440 clinical trials of new cancer medicines are recruiting patients in Florida. Biopharmaceutical companies are collaborating on the tests with such prominent institutions as **M.D. Anderson Cancer Center** and the **Florida Hospital Cancer Institute** in Orlando, the **H. Lee Moffitt Cancer Center and Research Institute** in Tampa, **University Cancer Institute** in Boynton Beach, the **Michael & Diane Bienes Comprehensive Cancer Center** at Holy Cross Hospital in Fort Lauderdale, and the **University of Miami's Sylvester Comprehensive Cancer Center**.

Diabetes affects more than 25 million Americans—more than 8 percent of the U.S. population—including 7 million people who are unaware they have the disease. In Florida, nearly 10 percent of adult residents have been diagnosed with diabetes, according to the Florida Department of Health. In 2012, 5,064 Floridians died from diabetes.

Currently, 76 diabetes clinical tests are seeking patients in Florida. The trials are being conducted at the **University of Miami**, the **Translational Research Institute at Florida Hospital** in Orlando, **Nemours Children's Clinic** in Jacksonville, Orlando and Pensacola; the **South Florida**

VA Foundation in Miami and the **University of Florida** in Gainesville.

Heart disease and stroke are the first and fourth leading disease causes of death in the United States and the second and fourth in Florida. According to the American Heart Association, more than 82 million Americans are affected by these diseases. In Florida, in 2012, more than 41,600 residents died from some form of heart disease and 8,372 died from a stroke, according to the Florida Department of Health.

Currently, 47 heart disease and 16 stroke clinical tests are seeking patients in Florida. The trials are being conducted at the **Orlando Heart Center**, the **University of Florida's Shands Cardiovascular Center** in Jacksonville, the **Heart and Vascular Institute of Florida** in Clearwater, the **Pepin Heart Institute** in Tampa, the **Baptist Cardiac and Vascular Institute** in Miami, and the **Bay Pines VA Healthcare System** in Bay Pines.

Mental illness affects nearly 60 million Americans suffering from some form of the disease—from anxiety to depression to schizophrenia to eating disorders. In Florida, about 660,000 adults live with serious mental illness and about 181,000 children live with serious mental health conditions, according to the National Alliance on Mental Illness.

Currently, 98 clinical trials for mental illness are recruiting patients in Florida. The trials are taking place at the **Janus Center for Psychiatric Research** in West Palm Beach, the **University of South Florida** in Tampa, the **University of Florida** in Gainesville and Jacksonville, the **Florida Clinical Research Center** in Bradenton and **Winter Park Memorial Hospital**.

Physicians and patients can find out about clinical trials being conducted all over the state in collaboration with local institutions by accessing www.clinicaltrials.gov, a database sponsored by the National Institutes of Health. Information on clinical trials and medicines in development is also available on www.phrma.org, the website of the Pharmaceutical Research and Manufacturers of America (PhRMA). Click on Innovation, Clinical Trials and then Research in Your Backyard.

What is the Clinical Trial Experience?

Clinical trials are research studies that grant participants early access to new medicines, which are being developed to help combat chronic and serious diseases. By volunteering for a clinical trial, patients take an active role in their healthcare by helping researchers test new treatments and find better ways of using existing treatments. In Florida alone, thousands of clinical trials have been conducted to target chronic conditions like asthma, cancer, diabetes, heart disease, mental illness and stroke.

Phases of Clinical Trials

There are three phases of testing used to evaluate potential new medicines:

Phase I—This phase is designed to test the safety of a new medicine. Researchers test the drug on a small group of people (20–80) and evaluate safety aspects of the drug, such as safe dosage range, the best way of administering the treatment (pill form vs. a shot, for example) and identifying what, if any, side effects there may be.

Phase II—This phase is designed to test effectiveness and safety. The treatment is given to 100 to 300 people to assess efficacy and try to identify less common side effects, which may appear when more people are tested. This

phase is usually placebo-controlled and double-blinded—neither patients nor doctors know if the patient is getting placebo or the medicine.

Phase III—This phase is designed to confirm effectiveness and safety, monitor side effects and compare the unapproved drug being tested to commonly used medications from the market to determine which is more effective. A large group (1,000–3,000) receives this treatment, and like Phase II, it is usually placebo-controlled and double-blinded.

Learning About and Accessing Clinical Trials

Patients can learn about clinical trials several ways. Healthcare providers are aware of clinical trials being conducted at hospitals, universities and other leading healthcare facilities, and these institutions can be valuable sources of information for patients looking to participate. Patients can also use hospital and university websites to find the trials being conducted in their area. More information about clinical trials and how to volunteer for one can be found at <http://centerwatch.com>, a PhRMA-recommended website.

What to Expect

Since clinical trials are often conducted in doctors' offices, patients may need to devote more time to physician visits and physical examinations. They may also have additional responsibilities, like keeping a daily log of their health. All prospective participants must sign an informed consent document saying they understand that the clinical trial is research, and that they can leave the trial at any time. After consulting their healthcare providers, patients can volunteer to participate, leading to a pre-screening interview. If they fit the criteria and requirements of the test, they can be enrolled.

Patient Expenses

Patients should ask during pre-screening interviews what it will cost them to participate in a clinical trial. Clinical trial sponsors usually pay for all research-related expenses and additional testing or physician visits required by the trial. Patients or their insurance companies may be asked to pay for routine treatments of their disease. And it's important to know some health plans do not pay for clinical trials. Patients should make it a point to learn if they or their insurance company will be assessed any fees and should determine if the insurance company will cover the expense of routine examinations. Patients who live a distance from the trial site should learn the clinic's policy for covering travel costs and living expenses.

The National Cancer Institute, for example, makes patients responsible for their own travel costs for the initial screening visits. Once a patient is enrolled, the Institute will pay for transportation costs for all subsequent trial-related visits. These patients will receive a small per diem for food and lodging.

New Generation Medicines in Development

Some of the medicines that have been tested in Florida are cutting-edge biotechnology drugs.

America's biopharmaceutical research companies are using biotechnology to develop hundreds of medicines and vaccines today. And Florida is one of the states where cutting-edge research and development work is being done.

Through biotechnology, new ways are being developed to not only more effectively treat disease, but also to predict and even prevent it.

Biotechnology medicines are developed through biological processes using living cells or organisms, rather than traditional chemical synthesis, the mainstay of pharmaceutical development for decades.

Such novel treatments use a variety of new approaches to treat disease. For example, a monoclonal antibody is a laboratory-made version of the naturally occurring immune system protein that binds to and neutralizes foreign invaders. Interferons are proteins that interfere with the ability of a cell to reproduce.

Antisense drugs, meanwhile, are medicines that interfere with the communication process which tells a cell to produce an unwanted protein. In addition, nanotechnology is being used in biotechnology research to provide drug-delivery systems, new treatments and diagnostics.

Many of the medicines in clinical testing, and those that have already been tested at Florida medical schools, hospitals and research centers, feature these technologies.

For example:

- A genetically-modified virus-based vaccine to treat melanoma, with clinical trials being conducted at the **Baptist Cancer Institute** in Jacksonville, **Lakeland Regional Cancer Center** in Lakeland, the **University of Miami and Mount Sinai Medical Center** in Miami, **M.D. Anderson Cancer Center Orlando**, **H. Lee Moffitt Cancer Center** in Tampa and the **Palm Beach Cancer Institute** in West Palm Beach.
- A recombinant fusion protein to treat diabetic macular edema with trials being conducted at the **National Ophthalmic Research Institute** in Fort Myers, the **Retina Group of Florida** in Fort Lauderdale, the **Central Florida Retina Institute** in Lakeland, **Ocala Eye Retina Consultants** and **Retina Associates of Sarasota**.
- A therapeutic vaccine, designed to jump-start the immune system to fight disease, is in development for lung cancer and melanoma, with clinical trials underway at the **H. Lee Moffitt Cancer Center and Research Institute** in Tampa.

The biotechnology medicines and vaccines that are being developed today are helping to expand the frontiers of science and patient care. And in Florida, as in other states, this innovation is the result of a successful collaboration of biopharmaceutical companies and local research institutions.

Conclusion

Biopharmaceutical research companies' close collaboration with clinicians and research institutions in Florida benefits patients, the state's economy and the advancement of science and patient care. Clinical trials provide stimulating biopharmaceutical research work and a reliable source of revenue for the states' medical schools, hospitals and contract research organizations and the medicines being tested are sometimes cutting-edge cell and protein treatments with the potential

to be safer and more effective than older chemical compound drugs.

What's more, Floridians considering participation in clinical trials of new drugs have a wide range of choices, including 696 tests of new medicines for the six most debilitating chronic diseases.

The Drug Discovery, Development and Approval Process

It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

Clinical Trials						
Discovery/ Preclinical Testing		Phase I	Phase II	Phase III	FDA	Phase IV
Years	6.5	1.5	2	3.5	1.5	
Test Population	Laboratory and animal studies	20 to 80 healthy volunteers	100 to 300 patient volunteers	1,000 to 3,000 patient volunteers	Review process/ approval	Additional post-marketing testing required by FDA
Purpose	Assess safety, biological activity and formulations	Determine safety and dosage	Evaluate effectiveness, look for side effects	Confirm effectiveness, monitor adverse reactions from long-term use		
Success Rate	5,000 compounds evaluated	5 enter trials			1 approved	

The Drug Development and Approval Process

The U.S. system of new drug approvals is perhaps the most rigorous in the world.

It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development. Only five in 5,000 compounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.

On average, it costs a company \$1.2 billion, including the cost of failures, to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.

Once a new compound has been identified in the laboratory, medicines are usually developed as follows:

Preclinical Testing. A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evaluated for safety.

Investigational New Drug Application (IND). After completing preclinical testing, a company files an IND with the U.S. Food and Drug Administration (FDA) to begin to test

the drug in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.

Clinical Trials, Phase I—Researchers test the drug in a small group of people, usually between 20 and 80 healthy adult volunteers, to evaluate its initial safety and tolerability profile, determine a safe dosage range, and identify potential side effects.

Clinical Trials, Phase II—The drug is given to volunteer patients, usually between 100 and 300, to see if it is effective, identify an optimal dose, and further evaluate its short-term safety.

Clinical Trials, Phase III—The drug is given to a larger, more diverse patient population, often involving between 1,000 and 3,000 patients (but sometime many more thousands),

to generate statistically significant evidence to confirm its safety and effectiveness. They are the longest studies, and usually take place in multiple sites around the world.

New Drug Application (NDA)/Biologic License Application (BLA). Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more.

Approval. Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects.

Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. PhRMA member companies invested an estimated \$48.5 billion in research and development in 2012.

The Good News – Many Clinical Trials are Still Recruiting

There are 696 clinical trials of new chronic disease drugs recruiting patients in Florida. These trials target the six most debilitating chronic conditions—cancer, heart disease, stroke, asthma, diabetes and mental illness.

Clinical Trials in Florida Communities						
Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Boca Raton	1	21	5	2	4	1
Boynton Beach	—	26	3	4	1	2
Clearwater	1	3	10	13	—	6
Daytona Beach	1	6	4	12	—	6
Fort Lauderdale	1	17	—	5	11	3
Fort Myers	—	56	—	2	11	2
Gainesville	1	22	2	10	12	2
Jacksonville	2	63	19	28	25	10
Melbourne	—	1	5	—	2	2
Miami	12	89	95	28	53	14
Orlando	1	71	16	13	48	3
Pensacola	1	9	2	3	—	—
Sarasota	3	30	1	7	5	7
St. Petersburg	—	44	7	8	9	5
Tallahassee	4	—	2	6	—	3
Tampa	4	164	12	16	22	7
West Palm Beach	—	17	4	2	16	2

Source: www.clinicaltrials.gov

Note: Search criteria = Florida, United States; Phase 0, 1, 2, 3; industry only. Search performed 8/31/2013. See Appendix for detailed information about these clinical trials.

Disease columns will not match totals in the Appendix because some clinical trials are recruiting in more than one city. This list of cities and towns is representative and not a complete list of where clinical trials are taking place in Florida.

The Good News—Many Clinical Trials are Still Recruiting

(continued)

Asthma—Leading Institutions Conducting Clinical Trials

Nemours Children’s Clinic, Jacksonville

Cancer—Leading Institutions Conducting Clinical Trials

Advanced Medical Specialties, Miami

All Children’s Hospital, St. Petersburg

Altus Research, Hollywood, Lake Worth

Ameriderm Research, Ormond Beach

AMPM Research, Miami

Arnold Palmer Hospital for Children, Orlando

Baptist Medical Center South, Jacksonville

Boca Raton Community Hospital, Boca Raton

Boca Raton Regional Hospital, Boca Raton

Broward Oncology Associates, Fort Lauderdale

Cancer and Blood Disease Center, Lecanto

Cancer Care of North Florida, Lake City

Cancer Center of Pasco-Pinellas, Holiday

Cancer Center of South Florida, Lake Worth

Cancer Centers of Florida, Ocoee

Cancer Institute of Florida, Orlando

Cancer Specialists of North Florida, Jacksonville

Cancer Specialists of North Florida Beaches,
St. Augustine

Center for GI Disorders, Hollywood

Center for Hematology-Oncology, Boca Raton

Cleveland Clinic Florida, Weston

Coastal Medical Center, Sarasota

Collaborative Research Group, Boynton Beach

Florida Cancer Institute-New Hope, Hudson

Florida Cancer Research Institute, Plantation

Florida Cancer Institute, New Port Richey

Florida Cancer Specialists, Fort Myers

Florida Cancer Specialists, Inverness

Florida Cancer Specialists, Sarasota

Florida Cancer Specialists, St. Petersburg

Florida Cancer Specialists and Research Institute,
Englewood

Florida Center for Dermatology, Jacksonville

Florida Hospital Cancer Institute, Orlando

Florida Hospital Transplant Institute, Orlando

Florida Oncology Associates-Orange Park, Jacksonville

Florida Urology Physicians, Fort Myers

FXM Research, Miami, Miramar

Gynecologic Oncology Associates, Miramar

H. Lee Moffitt Cancer Center and Research Institute,
Tampa

Halifax Health Medical Center, Daytona Beach

Hematology Oncology Associates of the Treasure Coast,
Port St. Lucie

Hematology Oncology Consultants PA, Orlando

Holy Cross Hospital-Michael and Dianne Bienes
Comprehensive Cancer Center, Fort Lauderdale

ICON Oncology, Orange Park

Integrated Community Oncology Network, Jacksonville	Radiant Research, Pinellas Park
International Dermatology Research, Miami	Sarah Cannon Research Institute, Sarasota
Jacksonville Center for Clinical Research, Jacksonville	Sarasota Memorial Hospital, Sarasota
Lake County Oncology and Hematology, Tavares, The Villages	Shafran Gastroenterology Center, Winter Park
Lakeland Regional Cancer Center, Lakeland	Shands Cancer Center at University of Florida, Gainesville
Lakes Research, Miami Lakes	South Florida Center for Gynecologic Oncology, Boca Raton
Lee Memorial Health System, Fort Myers	South Florida Medical Research, Aventura
Lynn Cancer Institute–Center for Hematology–Oncology, Boca Raton	Southeastern Center for Digestive Disorders and Pancreatic Cancer, Tampa
M.D. Anderson Cancer Center, Orlando	Space Coast Cancer Center, Titusville
Manatee Medical Research Institute, Bradenton	Specialists in Urology, Naples
Martin Health System, Stuart	Spencer Clinical Services, St. Petersburg
Mayo Clinic Florida, Jacksonville	St. Joseph’s Children’s Hospital of Tampa, Tampa
Medical Associates of Brevard Oncology/Hematology, Melbourne	Sylvester Comprehensive Cancer Center/University of Miami, Miami
Memorial Cancer Institute, Pembroke Pines	Tampa Bay Medical Research, Clearwater
Memorial Regional Cancer Center, Hollywood	Tampa General Hospital, Tampa
Miami Children’s Hospital, Miami	University Cancer Institute, Boynton Beach
Miami Research Associates, Miami	University of Florida, Gainesville
Mount Sinai Cancer Center, Miami Beach	University of Miami Miller School of Medicine, Miami
Nemours Children’s Clinic, Jacksonville	University of South Florida, Tampa
North Florida Dermatology Associates, Jacksonville	Urological Research Network, Hialeah
Ocala Oncology Center, Ocala	VA Medical Center, Miami
Ormond Medical Arts Pharmaceutical Research Center, Ormond Beach	Visions Clinical Research, Boynton Beach
Palm Beach Cancer Institute, West Palm Beach	Watson Clinic Center for Cancer Care and Research, Lakeland
Park Avenue Dermatology, Orange Park	Women’s Cancer Associates, St. Petersburg
Pasco Hernando Oncology Associates, Brooksville, New Port Richey	Woodlands Medical Specialists, Pensacola
Pinellas Urology, St. Petersburg	

Continued on page 16

The Good News—Many Clinical Trials are Still Recruiting

(continued from page 15)

Diabetes—Leading Institutions Conducting Clinical Trials

Advanced Pharma CR, Miami

Advanced Research Institute of Miami, Homestead

AGA Clinical Trials, Hialeah

ALL Medical Research, Cooper City

Arnold Palmer Hospital for Children, Orlando

Barry University School of Podiatric Medicine, Hialeah

Boca Raton Clinical Research Associates, Boca Raton

Clinical Research of Central Florida, Winter Haven

Clinical Research of Miami, Miami

Clinical Therapeutics Corporation, Coral Gables

Doctors Research Network, South Miami

FLCRI Global Research, Miami

Florida Hospital Memorial Medical Center,
Daytona Beach

Florida Neurovascular Institute, Tampa

FPA Clinical Research, Kissimmee

Genesis Clinical Research, Tampa

Gulfcoast Clinical Research Center, Fort Myers

International Research Associates, Hialeah

International Research Associates, Miami

MD Clinical, Hallandale Beach

Meridien Research, Bradenton, Brooksville,
St. Petersburg, Tampa

MIMA Century Research Associates, Melbourne

Nemours Children's Clinic, Jacksonville, Orlando,
Pensacola

Next Phase Clinical Trials, Miami Beach

Omega Research Consultants, Debary

Palm Harbor Medical Associates, Palm Harbor

Palm Springs Research Institute, Hialeah

Paul and Margaret Brand Research Center at
Barry University, Hialeah

Phase I Clinic: MRA Clinical Research, Miami

Research in Miami, Miami Beach

Retina Vitreous Associates of Florida, Clearwater,
St. Petersburg

SeaView Research, Miami

South Florida VA Foundation, Miami

South Miami Clinical Research, South Miami

Southeast Clinical Research, Chiefland, Jacksonville

SouthEast Medical Centre, Oakland Park

St. Paul Medical Research, Miami

Translational Research Institute at Florida Hospital,
Orlando

University of Florida Endocrinology & Diabetes,
Jacksonville

University of Florida, Gainesville

University of Miami Miller School of Medicine, Miami

Heart Disease—Leading Institutions Conducting Clinical Trials

Baptist Cardiac and Vascular Institute, Miami
Baptist Hospital of Miami, Miami
Bay Pines VA Healthcare System, Bay Pines
Bethesda Memorial Hospital, Boynton Beach
Cardiology Research Associates, Daytona Beach
Cardiovascular Research Center of South Florida,
Miami
Clearwater Cardiovascular Consultants, Clearwater
Cleveland Clinic Florida, Weston
Complete Cardiology Care, New Smyrna Beach
Daytona Heart Group, Daytona Beach
East Coast Institute for Research, St. Augustine
Elite Research and Clinical Trials, Aventura
First Coast Cardiovascular Institute, Jacksonville
Florida Heart Group, Orlando
Florida Hospital Pepin Heart Institute/
Dr. Kiran C. Patel Research Institute, Tampa
Florida Hospital, Cardiovascular Research Institute,
Orlando
Florida Neurovascular Institute, Tampa
Holy Cross Hospital, Fort Lauderdale
Infinity Clinical Research, Hollywood
Lakeland Regional Medical Clinic, Lakeland
Lynn Heart and Vascular Institute/Boca Raton
Regional Hospital, Boca Raton
Mayo Clinic Florida, Jacksonville
MediQuest Research, Ocala
Melbourne Cardiac Research Institute, Melbourne

Mercy Research Institute, Miami
MIMA Century Research Associates, Melbourne
Morton Plant Hospital, Heart and Vascular Institute of
Florida, Clearwater
Mount Sinai Medical Center, Miami Beach
Munroe Regional Medical Center, Ocala
New Phase Clinical Trials, Miami Beach
North Florida/South Georgia Health System,
Gainesville
Northside Hospital Heart & Vascular Institute,
St. Petersburg
Orlando Health Medical Center, Orlando
Orlando Heart Center, Orlando
Osceola Regional Medical Center, Kissimmee
S&W Clinical Research, Fort Lauderdale
St. Luke's Cardiology Associates, Jacksonville
Tallahassee Research Institute, Tallahassee
University of Florida, Division of Cardiovascular
Medicine, Gainesville
University of Florida, Shands Jacksonville
Cardiovascular Center, Jacksonville
University of Miami Health System/Jackson Memorial
Hospital, Miami
University of Miami McKnight Brain Institute, Miami
University of Miami/Miller School of Medicine, Miami
University of South Florida, Tampa
Watson Medical Clinic for Research, Lakeland
West Coast Arrhythmia Center, Hudson

Continued on page 18

The Good News—Many Clinical Trials are Still Recruiting

(continued from page 17)

Mental Illness—Leading Institutions Conducting Clinical Trials

Accurate Clinical Trials, Kissimmee

Advanced Mental Health Care, Juno Beach,
Royal Palm Beach

Alzheimer's Research and Treatment Center,
Lake Worth

AMB Research Center, Miami

Amedica Research Institute, Hialeah

Axiom Clinical Research of Florida, Tampa

Bay Pines VA Healthcare System, Bay Pines

Brian Matters Research, Delray Beach

Center for Marital and Sexual Health of South Florida,
West Palm Beach

Clinical Neuroscience Solutions, Jacksonville, Orlando

Clinical Physiology Associates, Fort Myers

Clinical Research of Central Florida, Winter Haven

Clinical Research of South Florida, Coral Gables

CNS Clinical Research Group, Coral Springs

CNS Healthcare, Orlando

Compass Research, Leesburg, Orlando

Compass Research East, Oviedo

Comprehensive Clinical Development, St. Petersburg

Comprehensive Neuroscience, St. Petersburg

Fidelity Clinical Research, Lauderhill, North Miami

Florida Clinical Research Center, Bradenton, Maitland

Gulfcoast Clinical Research Center, Fort Myers

Janus Center for Psychiatric Research, West Palm Beach

Kendall South Medical Center, Miami

Kolin Research Group, Winter Park

Lake Mary Pediatrics, Orange City

Lakeside Behavioral Health, Orlando

Mailman Segal Center at Nova Southeastern University,
Fort Lauderdale

MD Clinical, Hallandale Beach

Medical Research Group of Central Florida, Sanford

Meridien Research, Bradenton, Brooksville,
St. Petersburg

Miami Jewish Health System, Miami

Miami Research Associates, South Miami

Neurology Associates of Ormond Beach,
Ormond Beach

Neuropsychiatric Research Center of Southwest
Florida, Fort Myers

Nova Southeastern University Clinic, Fort Lauderdale

Ocean Sleep Disorders Center, Ormond Beach

PAB Clinical Research, Brandon

Palm Beach Neurological Center/Advanced Research
Consultants, Palm Beach Gardens

Premiere Research Institute, West Palm Beach

Psychiatric Associates, Lake City

Research Centers of America, Oakland Park

Resurgence Group, Palm Harbor

Sarkis Clinical Trials, Gainesville

Scientific Clinical Research, North Miami

Segal Institute for Clinical Research, North Miami

SJS Clinical Research, Destin

Stedman Clinical Trials, Tampa

Suncoast Clinical Research, New Port Richey

The Roskamp Institute, Sarasota

University of Florida, Gainesville

University of Miami Miller School of Medicine, Miami

University of South Florida, Department of Psychiatry
and Neurosciences, Tampa

Winter Park Memorial Hospital, Winter Park

Stroke—Leading Institutions Conducting Clinical Trials

Florida Hospital, Orlando

Florida Neurovascular Institute, Tampa

Intercoastal Medical Group, Sarasota

MIMA Century Research Associates, Melbourne

Sarasota Memorial Hospital, Sarasota

University of Florida, Gainesville

University of Florida, Jacksonville

University of Miami Hospital, Miami

Appendix

The clinical trials listed here involve tests that have not yet started recruiting patients or are just now seeking volunteers to participate. This information is potentially valuable to patients still seeking effective treatments for their chronic diseases. It provides a new therapeutic option to discuss with physicians.

Those interested in obtaining more information about certain trials can use the URL code listed for each test to log onto *www.clinicaltrials.gov*, the clinical tests database of the National Institutes of Health.

Asthma

(19 clinical trials recruiting)

Study 1:

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

<http://ClinicalTrials.gov/show/NCT01854047>

Study 2:

Efficacy and Safety of QGE031 versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma

<http://ClinicalTrials.gov/show/NCT01716754>

Study 3:

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Inadequately Controlled Asthma Subjects With High Bronchodilator Reversibility

<http://ClinicalTrials.gov/show/NCT01902290>

Study 4:

A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223 AM2)

<http://ClinicalTrials.gov/show/NCT01502371>

Study 5:

A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012 AM2)

<http://ClinicalTrials.gov/show/NCT01656395>

Study 6:

A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

<http://ClinicalTrials.gov/show/NCT01867125>

Study 7:

A Study of Lebrikizumab in Patients With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication

<http://ClinicalTrials.gov/show/NCT01868061>

Study 8:

A Study of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

<http://ClinicalTrials.gov/show/NCT01875003>

Study 9:

A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)

<http://ClinicalTrials.gov/show/NCT01582503>

Study 10:

A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

<http://ClinicalTrials.gov/show/NCT01479595>

Study 11:

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (Mcg), FF/VI 100/25 Mcg, and FF 100 Mcg in Adults and Adolescents With Persistent Asthma

<http://ClinicalTrials.gov/show/NCT01686633>

Study 12:

A Dose-ranging Study of Fluticasone Furoate (FF)

<http://ClinicalTrials.gov/show/NCT01563029>

Study 13:

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children

<http://ClinicalTrials.gov/show/NCT01573767>

Study 14:

Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011 AM2)

<http://ClinicalTrials.gov/show/NCT01624974>

Study 15:

Evaluate Safety of T/I on Diabetic Subjects With Mild Obstructive Pulmonary Disease

<http://ClinicalTrials.gov/show/NCT00642616>

Study 16:

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

<http://ClinicalTrials.gov/show/NCT01673672>

Study 17:

A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients

<http://ClinicalTrials.gov/show/NCT01836471>

Study 18:

Genotype Stratified Pharmacokinetic Study of Montelukast

<http://ClinicalTrials.gov/show/NCT01086527>

Study 19:

Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

<http://ClinicalTrials.gov/show/NCT01700192>

Cancer (440 clinical trials recruiting)

Study 1:

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

<http://ClinicalTrials.gov/show/NCT01326871>

Study 2:

A Study of LY2228820 for Recurrent Ovarian Cancer

<http://ClinicalTrials.gov/show/NCT01663857>

Study 3:

Maximum Tolerated Dose Study of Belinostat (PXD-101) in Combination With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Stage IV Non-Small-Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01310244>

Study 4:

A Study to Test Safety and Efficacy of IMGN901 in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01237678>

Study 5:

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

<http://ClinicalTrials.gov/show/NCT01493505>

Study 6:

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

<http://ClinicalTrials.gov/show/NCT01666444>

Study 7:

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

<http://ClinicalTrials.gov/show/NCT01605227>

Study 8:

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

<http://ClinicalTrials.gov/show/NCT00858364>

Study 9:

TRINOVA-2: Trebananib in Ovarian Cancer-2

<http://ClinicalTrials.gov/show/NCT01281254>

Study 10:

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

<http://ClinicalTrials.gov/show/NCT01625260>

Study 11:

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

<http://ClinicalTrials.gov/show/NCT01379534>

Study 12:

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01578655>

Study 13:

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01664923>

Study 14:

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01345019>

Study 15:

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

<http://ClinicalTrials.gov/show/NCT01347645>

Study 16:

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

<http://ClinicalTrials.gov/show/NCT00925600>

Study 17:

Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

<http://ClinicalTrials.gov/show/NCT01745367>

Study 18:

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01836432>

Study 19:

An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01822756>

Study 20:

A Study of Onartuzumab (MetMab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

<http://ClinicalTrials.gov/show/NCT01456325>

Study 21:

A Phase 1 Study to Evaluate MEDI4736

<http://ClinicalTrials.gov/show/NCT01693562>

Study 22:

A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer

<http://ClinicalTrials.gov/show/NCT01740427>

Study 23:

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

<http://ClinicalTrials.gov/show/NCT01358877>

Study 24:

A Study of Onartuzumab (MetMab) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

<http://ClinicalTrials.gov/show/NCT01662869>

Study 25:

Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

<http://ClinicalTrials.gov/show/NCT00320710>

Study 26:

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

<http://ClinicalTrials.gov/show/NCT01482715>

Study 27:

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01322490>

Study 28:

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

<http://ClinicalTrials.gov/show/NCT01772472>

Study 29:

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01373164>

Study 30:

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

<http://ClinicalTrials.gov/show/NCT00696072>

Study 31:

Immunotherapy Study for Surgically Resected Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01072981>

Study 32:

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01620515>

Study 33:

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

<http://ClinicalTrials.gov/show/NCT01170650>

Study 34:

The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01506609>

Study 35:

CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2

<http://ClinicalTrials.gov/show/NCT01877811>

Study 36:

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01177397>

Study 37:

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT01361607>

Study 38:

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

<http://ClinicalTrials.gov/show/NCT01846611>

Study 39:

Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

<http://ClinicalTrials.gov/show/NCT01337089>

Study 40:

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

<http://ClinicalTrials.gov/show/NCT01220128>

Study 41:

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01685138>

Study 42:

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

<http://ClinicalTrials.gov/show/NCT01479244>

Study 43:

A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01630733>

Study 44:

A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01619423>

Study 45:

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

<http://ClinicalTrials.gov/show/NCT01610284>

Study 46:

Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab

<http://ClinicalTrials.gov/show/NCT01132664>

Study 47:

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

<http://ClinicalTrials.gov/show/NCT01685268>

Study 48:

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advanced Breast Cancer

<http://ClinicalTrials.gov/show/NCT01783444>

Study 49:

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

<http://ClinicalTrials.gov/show/NCT01421472>

Study 50:

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

<http://ClinicalTrials.gov/show/NCT01420081>

Study 51:

Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT00733850>

Study 52:

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01374425>

Study 53:

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01615120>

Study 54:

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01308580>

Study 55:

A Study Of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01846416>

Study 56:

STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01765582>

Study 57:

Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy

<http://ClinicalTrials.gov/show/NCT01521143>

Study 58:

Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01493843>

Study 59:

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

<http://ClinicalTrials.gov/show/NCT01773785>

Study 60:

A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

<http://ClinicalTrials.gov/show/NCT01774786>

Study 61:

Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

<http://ClinicalTrials.gov/show/NCT01485861>

Study 62:

A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01769391>

Study 63:

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01839487>

Study 64:

A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

<http://ClinicalTrials.gov/show/NCT01351415>

Study 65:

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

<http://ClinicalTrials.gov/show/NCT01296555>

Study 66:

A Study of Onartuzumab (MetMab) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01519804>

Study 67:

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation

<http://ClinicalTrials.gov/show/NCT01887886>

Study 68:

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01740336>

Study 69:

Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01663727>

Study 70:

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

<http://ClinicalTrials.gov/show/NCT01565083>

Study 71:

A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01588028>

Study 72:

A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment

<http://ClinicalTrials.gov/show/NCT01801111>

Study 73:

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

<http://ClinicalTrials.gov/show/NCT01437566>

Study 74:

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

<http://ClinicalTrials.gov/show/NCT01295827>

Study 75:

A Study in Advanced Cancer

<http://ClinicalTrials.gov/show/NCT01226485>

Study 76:

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01594398>

Study 77:

Ph I Dose Escalation Study of Antibody-drug Conjugate IMMU-132 in Patients With Advanced Epithelial Cancers

<http://ClinicalTrials.gov/show/NCT01631552>

Study 78:

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

<http://ClinicalTrials.gov/show/NCT01578239>

Study 79:

Safety and Tolerability Study in Solid Tumors

<http://ClinicalTrials.gov/show/NCT01803282>

Study 80:

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01576666>

Study 81:

SGI-110 in Combination With Carboplatin in Ovarian Cancer

<http://ClinicalTrials.gov/show/NCT01696032>

Study 82:

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

<http://ClinicalTrials.gov/show/NCT00790816>

Study 83:

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

<http://ClinicalTrials.gov/show/NCT01300533>

Study 84:

SC16LD6.5 in Recurrent Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01901653>

Study 85:

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

<http://ClinicalTrials.gov/show/NCT01154140>

Study 86:

Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

<http://ClinicalTrials.gov/show/NCT01911325>

Study 87:

A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Cisplatin in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)

<http://ClinicalTrials.gov/show/NCT01859741>

Study 88:

Study of PX-866 and Docetaxel in Solid Tumors

<http://ClinicalTrials.gov/show/NCT01204099>

Study 89:

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

<http://ClinicalTrials.gov/show/NCT01597193>

Study 90:

A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

<http://ClinicalTrials.gov/show/NCT01469793>

Study 91:

Open Label Extension Study of Conatumumab and AMG 479

<http://ClinicalTrials.gov/show/NCT01327612>

Study 92:

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01692262>

Study 93:

Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor

<http://ClinicalTrials.gov/show/NCT01478178>

Study 94:

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

<http://ClinicalTrials.gov/show/NCT01712217>

Study 95:

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

<http://ClinicalTrials.gov/show/NCT01889238>

Study 96:

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

<http://ClinicalTrials.gov/show/NCT00045968>

Study 97:

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

<http://ClinicalTrials.gov/show/NCT01828112>

Study 98:

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

<http://ClinicalTrials.gov/show/NCT00680992>

Study 99:

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

<http://ClinicalTrials.gov/show/NCT01685060>

Study 100:

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01353625>

Study 101:

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01632306>

Study 102:

NOLAN: Naproxen or Loratadine and Neulasta

<http://ClinicalTrials.gov/show/NCT01712009>

Study 103:

Study Of Dacomitinib In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

<http://ClinicalTrials.gov/show/NCT01465802>

Study 104:

Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01849744>

Study 105:

A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01871805>

Study 106:

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

<http://ClinicalTrials.gov/show/NCT01798485>

Study 107:

Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer

<http://ClinicalTrials.gov/show/NCT01309230>

Study 108:

Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

<http://ClinicalTrials.gov/show/NCT01751308>

Study 109:

A Study of Onartuzumab (MetMAB) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01496742>

Study 110:

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01001377>

Study 111:

Study of MM-398 With or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01494506>

Study 112:

A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations

<http://ClinicalTrials.gov/show/NCT01336634>

Study 113:

A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01709734>

Study 114:

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer

<http://ClinicalTrials.gov/show/NCT01617668>

Study 115:

Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01375842>

Study 116:

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01597388>

Study 117:

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

<http://ClinicalTrials.gov/show/NCT01607957>

Study 118:

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

<http://ClinicalTrials.gov/show/NCT01351350>

Study 119:

Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane

<http://ClinicalTrials.gov/show/NCT01461915>

Study 120:

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01792479>

Study 121:

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01427946>

Study 122:

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

<http://ClinicalTrials.gov/show/NCT01528345>

Study 123:

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01827267>

Study 124:

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01792050>

Study 125:

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer

<http://ClinicalTrials.gov/show/NCT01602380>

Study 126:

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

<http://ClinicalTrials.gov/show/NCT01634061>

Study 127:

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

<http://ClinicalTrials.gov/show/NCT00986661>

Study 128:

A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01657799>

Study 129:

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

<http://ClinicalTrials.gov/show/NCT01572727>

Study 130:

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment

<http://ClinicalTrials.gov/show/NCT01750281>

Study 131:

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

<http://ClinicalTrials.gov/show/NCT01828021>

Study 132:

Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer

<http://ClinicalTrials.gov/show/NCT01778803>

Study 133:

A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01652482>

Study 134:

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

<http://ClinicalTrials.gov/show/NCT01695044>

Study 135:

Study of MK-3475 in Participants With Advanced Solid Tumors (MK-3475-012)

<http://ClinicalTrials.gov/show/NCT01848834>

Study 136:

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01297491>

Study 137:

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01395758>

Study 138:

A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer

<http://ClinicalTrials.gov/show/NCT01788566>

Study 139:

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01562015>

Study 140:

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

<http://ClinicalTrials.gov/show/NCT01395914>

Study 141:

Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer

<http://ClinicalTrials.gov/show/NCT01698281>

Study 142:

FOLFOX6m Plus SIR-Spheres Microspheres vs. FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01721954>

Study 143:

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

<http://ClinicalTrials.gov/show/NCT01594723>

Study 144:

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)

<http://ClinicalTrials.gov/show/NCT01387269>

Study 145:

A Study of MPDL3280A Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Platinum Failure

<http://ClinicalTrials.gov/show/NCT01903993>

Study 146:

A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

<http://ClinicalTrials.gov/show/NCT01304524>

Study 147:

Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01642004>

Study 148:

Phase II Study of GTx024 in Women With Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01616758>

Study 149:

A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01862081>

Study 150:

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

<http://ClinicalTrials.gov/show/NCT01516307>

Study 151:

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in First-Line or in Switch Maintenance in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01454102>

Study 152:

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

<http://ClinicalTrials.gov/show/NCT01491737>

Study 153:

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

<http://ClinicalTrials.gov/show/NCT01513083>

Study 154:

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

<http://ClinicalTrials.gov/show/NCT01764477>

Study 155:

Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

<http://ClinicalTrials.gov/show/NCT01285609>

Study 156:

A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004 AM6)

<http://ClinicalTrials.gov/show/NCT01357161>

Study 157:

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049 AM1)

<http://ClinicalTrials.gov/show/NCT01295632>

Study 158:

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

<http://ClinicalTrials.gov/show/NCT01479465>

Study 159:

An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)

<http://ClinicalTrials.gov/show/NCT01121588>

Study 160:

Study of KB004 in Subjects With Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01211691>

Study 161:

A Study of DS-2248, in Subjects With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01288430>

Study 162:

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM3)

<http://ClinicalTrials.gov/show/NCT01254630>

Study 163:

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01483027>

Study 164:

An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+

<http://ClinicalTrials.gov/show/NCT01116245>

Study 165:

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

<http://ClinicalTrials.gov/show/NCT01628913>

Study 166:

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

<http://ClinicalTrials.gov/show/NCT01611857>

Study 167:

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

<http://ClinicalTrials.gov/show/NCT01516736>

Study 168:

Video Impact on Neulasta Education

<http://ClinicalTrials.gov/show/NCT01752907>

Study 169:

A Study of LY2875358 in Patients With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT01287546>

Study 170:

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT00994123>

Study 171:

Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer

<http://ClinicalTrials.gov/show/NCT01229865>

Study 172:

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

<http://ClinicalTrials.gov/show/NCT01364415>

Study 173:

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment

<http://ClinicalTrials.gov/show/NCT00812240>

Study 174:

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01160211>

Study 175:

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

<http://ClinicalTrials.gov/show/NCT01461538>

Study 176:

A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01160744>

Study 177:

Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Non-squamous NSCLC

<http://ClinicalTrials.gov/show/NCT01673867>

Study 178:

Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib

<http://ClinicalTrials.gov/show/NCT01487265>

Study 179:

A Phase 1 Study of IPI-145 in Patients With Advanced Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01476657>

Study 180:

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

<http://ClinicalTrials.gov/show/NCT01231594>

Study 181:

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01298570>

Study 182:

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

<http://ClinicalTrials.gov/show/NCT01345682>

Study 183:

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

<http://ClinicalTrials.gov/show/NCT01616199>

Study 184:

A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

<http://ClinicalTrials.gov/show/NCT01490866>

Study 185:

5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer

<http://ClinicalTrials.gov/show/NCT01749956>

Study 186:

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01449058>

Study 187:

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

<http://ClinicalTrials.gov/show/NCT01750580>

Study 188:

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01302405>

Study 189:

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01543698>

Study 190:

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

<http://ClinicalTrials.gov/show/NCT01140607>

Study 191:

Everolimus Plus Best Supportive Care vs. Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)

<http://ClinicalTrials.gov/show/NCT01524783>

Study 192:

Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

<http://ClinicalTrials.gov/show/NCT01527487>

Study 193:

Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT01460537>

Study 194:

Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer

<http://ClinicalTrials.gov/show/NCT01388647>

Study 195:

Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C

<http://ClinicalTrials.gov/show/NCT01577758>

Study 196:

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

<http://ClinicalTrials.gov/show/NCT01213472>

Study 197:

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

<http://ClinicalTrials.gov/show/NCT01433263>

Study 198:

Trial of Poor Performance Status Patients (ToPPS)

<http://ClinicalTrials.gov/show/NCT00892710>

Study 199:

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

<http://ClinicalTrials.gov/show/NCT01629758>

Study 200:

BKM120 for Patients With PI3K-activated Tumors

<http://ClinicalTrials.gov/show/NCT01833169>

Study 201:

Triciribine and Carboplatin in Ovarian Cancer

<http://ClinicalTrials.gov/show/NCT01690468>

Study 202:

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

<http://ClinicalTrials.gov/show/NCT01256268>

Study 203:

REDECT 2: RENal Masses: Pivotal Trial to DEtect Clear Cell Renal Cell Carcinoma With PET/CT

<http://ClinicalTrials.gov/show/NCT01762592>

Study 204:

A Study of Onartuzumab as Single Agent and in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma

<http://ClinicalTrials.gov/show/NCT01897038>

Study 205:

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

<http://ClinicalTrials.gov/show/NCT01859026>

Study 206:

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

<http://ClinicalTrials.gov/show/NCT00968968>

Study 207:

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

<http://ClinicalTrials.gov/show/NCT01436656>

Study 208:

Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor

<http://ClinicalTrials.gov/show/NCT01404650>

Study 209:

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

<http://ClinicalTrials.gov/show/NCT01450761>

Study 210:

A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

<http://ClinicalTrials.gov/show/NCT01305941>

Study 211:

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

<http://ClinicalTrials.gov/show/NCT01207492>

Study 212:

Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

<http://ClinicalTrials.gov/show/NCT01294670>

Study 213:

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

<http://ClinicalTrials.gov/show/NCT01226719>

Study 214:

Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01829113>

Study 215:

Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01417806>

Study 216:

A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck

<http://ClinicalTrials.gov/show/NCT01921426>

Study 217:

Patient Controlled Tissue Expansion for Breast Reconstruction

<http://ClinicalTrials.gov/show/NCT01425268>

Study 218:

A Study of LY2940680 in Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01722292>

Study 219:

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

<http://ClinicalTrials.gov/show/NCT01008150>

Study 220:

Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

<http://ClinicalTrials.gov/show/NCT01905813>

Study 221:

Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors

<http://ClinicalTrials.gov/show/NCT01765790>

Study 222:

Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets

<http://ClinicalTrials.gov/show/NCT01581307>

Study 223:

Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650 AM1)

<http://ClinicalTrials.gov/show/NCT01463696>

Study 224:

An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVENTM in Subjects With Cancer Who Also Have Impaired Renal Function

<http://ClinicalTrials.gov/show/NCT01418677>

Study 225:

Phase I Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation

<http://ClinicalTrials.gov/show/NCT01915498>

Study 226:

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

<http://ClinicalTrials.gov/show/NCT01373294>

Study 227:

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

<http://ClinicalTrials.gov/show/NCT01520220>

Study 228:

Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT00906282>

Study 229:

Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM)

<http://ClinicalTrials.gov/show/NCT01931098>

Study 230:

Intravenous Administration of RGI-2001 in Patient Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

<http://ClinicalTrials.gov/show/NCT01379209>

Study 231:

A Study of Axitinib in Advanced Carcinoid Tumors

<http://ClinicalTrials.gov/show/NCT01435122>

Study 232:

A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients

<http://ClinicalTrials.gov/show/NCT01795586>

Study 233:

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

<http://ClinicalTrials.gov/show/NCT01401959>

Study 234:

Study With Lead-in Cohort of 5-FU, Oxaliplatin, Lapatinib & 5-FU for Patients With HER2 Positive Esophagogastric Cancer

<http://ClinicalTrials.gov/show/NCT01769508>

Study 235:

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma or CLL

<http://ClinicalTrials.gov/show/NCT01775631>

Study 236:

Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies

<http://ClinicalTrials.gov/show/NCT01683149>

Study 237:

Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer

<http://ClinicalTrials.gov/show/NCT01376453>

Study 238:

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

<http://ClinicalTrials.gov/show/NCT01301716>

Study 239:

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

<http://ClinicalTrials.gov/show/NCT01767467>

Study 240:

Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy

<http://ClinicalTrials.gov/show/NCT01592370>

Study 241:

Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients

<http://ClinicalTrials.gov/show/NCT01724866>

Study 242:

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

<http://ClinicalTrials.gov/show/NCT00515411>

Study 243:

Phase 1/2 Dose-Escalation, Safety, PK & PD Study of BVD-523, an ERK 1/2 Inhibitor, in Patients With Advanced Malignancies

<http://ClinicalTrials.gov/show/NCT01781429>

Study 244:

Phase I Trial of Combination of FOLFIRI and SOM 230

<http://ClinicalTrials.gov/show/NCT01434069>

Study 245:

A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy

<http://ClinicalTrials.gov/show/NCT01926444>

Study 246:

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

<http://ClinicalTrials.gov/show/NCT01523171>

Study 247:

Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT00884676>

Study 248:

Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects

<http://ClinicalTrials.gov/show/NCT00937950>

Study 249:

Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

<http://ClinicalTrials.gov/show/NCT01844583>

Study 250:

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01767766>

Study 251:

A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01799889>

Study 252:

A Phase 2 of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01796470>

Study 253:

P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01854567>

Study 254:

Sorafenib Long Term Extension Program (STEP)

<http://ClinicalTrials.gov/show/NCT00625378>

Study 255:

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

<http://ClinicalTrials.gov/show/NCT01531205>

Study 256:

An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

<http://ClinicalTrials.gov/show/NCT01585987>

Study 257:

A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT01262651>

Study 258:

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

<http://ClinicalTrials.gov/show/NCT01190189>

Study 259:

HepaSphere/QuadraspHERE Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

<http://ClinicalTrials.gov/show/NCT01387932>

Study 260:

A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy

<http://ClinicalTrials.gov/show/NCT01234519>

Study 261:

Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

<http://ClinicalTrials.gov/show/NCT01514864>

Study 262:

CRS-207 Cancer Vaccine in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma

<http://ClinicalTrials.gov/show/NCT01675765>

Study 263:

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

<http://ClinicalTrials.gov/show/NCT01814813>

Study 264:

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

<http://ClinicalTrials.gov/show/NCT01593228>

Study 265:

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01321346>

Study 266:

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

<http://ClinicalTrials.gov/show/NCT01763164>

Study 267:

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

<http://ClinicalTrials.gov/show/NCT01332266>

Study 268:

An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols

<http://ClinicalTrials.gov/show/NCT01178411>

Study 269:

Dabrafenib Plus Trametinib vs. Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

<http://ClinicalTrials.gov/show/NCT01597908>

Study 270:

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

<http://ClinicalTrials.gov/show/NCT01735968>

Study 271:

Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme

<http://ClinicalTrials.gov/show/NCT01349660>

Study 272:

Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung

<http://ClinicalTrials.gov/show/NCT01877083>

Study 273:

A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants

<http://ClinicalTrials.gov/show/NCT01900652>

Study 274:

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

<http://ClinicalTrials.gov/show/NCT01523587>

Study 275:

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

<http://ClinicalTrials.gov/show/NCT01693068>

Study 276:

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

<http://ClinicalTrials.gov/show/NCT01556490>

Study 277:

Treatment of Blood Clots in Children With Cancer

<http://ClinicalTrials.gov/show/NCT00952380>

Study 278:

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

<http://ClinicalTrials.gov/show/NCT01886287>

Study 279:

Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

<http://ClinicalTrials.gov/show/NCT01147809>

Study 280:

Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder, Urethra, Ureter, or Renal Pelvis Carcinoma

<http://ClinicalTrials.gov/show/NCT01282463>

Study 281:

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

<http://ClinicalTrials.gov/show/NCT01480479>

Study 282:

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

<http://ClinicalTrials.gov/show/NCT01353222>

Study 283:

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Refractory Carcinoid Syndrome)

<http://ClinicalTrials.gov/show/NCT01677910>

Study 284:

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01335399>

Study 285:

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01478048>

Study 286:

Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma

<http://ClinicalTrials.gov/show/NCT01909453>

Study 287:

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma

<http://ClinicalTrials.gov/show/NCT01271504>

Study 288:

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

<http://ClinicalTrials.gov/show/NCT00916409>

Study 289:

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

<http://ClinicalTrials.gov/show/NCT01784068>

Study 290:

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01734928>

Study 291:

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01564537>

Study 292:

MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01850524>

Study 293:

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01432353>

Study 294:

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

<http://ClinicalTrials.gov/show/NCT01568866>

Study 295:

**BT062 in Combination With Lenalidomide/
Dexamethasone in Patients With Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01638936>

Study 296:

**Phase 3 Trial of Autologous Dendritic Cell
Immunotherapy (AGS-003) Plus Standard Treatment of
Advanced Renal Cell Carcinoma (RCC)**

<http://ClinicalTrials.gov/show/NCT01582672>

Study 297:

**A Study of Cabozantinib (XL184) vs. Everolimus in
Subjects With Metastatic Renal Cell Carcinoma**

<http://ClinicalTrials.gov/show/NCT01865747>

Study 298:

**A Phase 2 Study of ASONEP™ to Treat Unresectable
and Refractory Renal Cell Carcinoma**

<http://ClinicalTrials.gov/show/NCT01762033>

Study 299:

**Open-label Study of TH-302 and Dexamethasone With
or Without Bortezomib in Subjects With Relapsed/
Refractory Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01522872>

Study 300:

**Study of Vosaroxin or Placebo in Combination
With Cytarabine in Patients With First Relapsed or
Refractory Acute Myeloid Leukemia (AML)**

<http://ClinicalTrials.gov/show/NCT01191801>

Study 301:

**Aplidin—Dexamethasone in Relapsed/Refractory
Myeloma**

<http://ClinicalTrials.gov/show/NCT01102426>

Study 302:

**Anti-CXCR4 (BMS-936564) Alone and in Combination
With Lenalidomide/Dexamethasone or Bortezomib/
Dexamethasone in Relapsed/Refractory Multiple
Myeloma**

<http://ClinicalTrials.gov/show/NCT01359657>

Study 303:

Phase 1 SAR650984 Combination With Lenalidomide

<http://ClinicalTrials.gov/show/NCT01749969>

Study 304:

**Study of Safety & Efficacy of the Combination of
LJM716 & BYL719 in Patients With Previously Treated
Esophageal Squamous Cell Carcinoma (ESCC)**

<http://ClinicalTrials.gov/show/NCT01822613>

Study 305:

**A Phase 1/2 Randomized, Blinded, Placebo Controlled
Study of Ipilimumab in Combination With INCB024360
or Placebo in Subjects With Unresectable or Metastatic
Melanoma**

<http://ClinicalTrials.gov/show/NCT01604889>

Study 306:

**Ponatinib in Newly Diagnosed Chronic Myeloid
Leukemia (CML) (EPIC)**

<http://ClinicalTrials.gov/show/NCT01650805>

Study 307:

**Study of the Combination of Panobinostat and
Carfilzomib in Patients With Relapsed/Refractory
Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01496118>

Study 308:

**Cyclophosphamide, Topotecan, and Bevacizumab
(CTB) in Patients With Relapsed/Refractory Ewing's
Sarcoma and Neuroblastoma**

<http://ClinicalTrials.gov/show/NCT01492673>

Study 309:

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

<http://ClinicalTrials.gov/show/NCT01696461>

Study 310:

Refametinib in RAS Mutant Hepatocellular Carcinoma (HCC)

<http://ClinicalTrials.gov/show/NCT01915589>

Study 311:

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

<http://ClinicalTrials.gov/show/NCT01432600>

Study 312:

Combination Plerixafor (AMD3100) and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT00903968>

Study 313:

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT00948922>

Study 314:

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01054144>

Study 315:

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

<http://ClinicalTrials.gov/show/NCT01351935>

Study 316:

Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

<http://ClinicalTrials.gov/show/NCT01488487>

Study 317:

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

<http://ClinicalTrials.gov/show/NCT01657591>

Study 318:

Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma

<http://ClinicalTrials.gov/show/NCT01606345>

Study 319:

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

<http://ClinicalTrials.gov/show/NCT01466153>

Study 320:

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

<http://ClinicalTrials.gov/show/NCT01842646>

Study 321:

ADAM-Afatinib Diarrhea Assessment and Management

<http://ClinicalTrials.gov/show/NCT01814553>

Study 322:

A Study of Onartuzumab (MetMAB) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma

<http://ClinicalTrials.gov/show/NCT01632228>

Study 323:

A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection

<http://ClinicalTrials.gov/show/NCT01682083>

Study 324:

Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma

<http://ClinicalTrials.gov/show/NCT01774344>

Study 325:

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma

<http://ClinicalTrials.gov/show/NCT01844505>

Study 326:

BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

<http://ClinicalTrials.gov/show/NCT01667419>

Study 327:

coBRIM: A Phase 3 Study Comparing GDC-0973 (Cobimetinib), a MEK Inhibitor, in Combination With Vemurafenib vs. Vemurafenib Alone in Patients With Metastatic Melanoma

<http://ClinicalTrials.gov/show/NCT01689519>

Study 328:

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

<http://ClinicalTrials.gov/show/NCT01721746>

Study 329:

Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma

<http://ClinicalTrials.gov/show/NCT01709162>

Study 330:

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

<http://ClinicalTrials.gov/show/NCT01546571>

Study 331:

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)

<http://ClinicalTrials.gov/show/NCT01704287>

Study 332:

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients

<http://ClinicalTrials.gov/show/NCT01804829>

Study 333:

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

<http://ClinicalTrials.gov/show/NCT01210495>

Study 334:

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

<http://ClinicalTrials.gov/show/NCT01673854>

Study 335:

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

<http://ClinicalTrials.gov/show/NCT01343277>

Study 336:

Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

<http://ClinicalTrials.gov/show/NCT01817530>

Study 337:

Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC

<http://ClinicalTrials.gov/show/NCT01668784>

Study 338:

A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma

<http://ClinicalTrials.gov/show/NCT01781572>

Study 339:

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma

<http://ClinicalTrials.gov/show/NCT01777776>

Study 340:

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy

<http://ClinicalTrials.gov/show/NCT01755767>

Study 341:

A Phase III Study of Oral LDE225 Versus (vs) Temozolomide (TMZ) in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

<http://ClinicalTrials.gov/show/NCT01708174>

Study 342:

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine

<http://ClinicalTrials.gov/show/NCT01397825>

Study 343:

SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

<http://ClinicalTrials.gov/show/NCT01752933>

Study 344:

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

<http://ClinicalTrials.gov/show/NCT01519323>

Study 345:

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064: CHECKpoint Pathway and nivoluMab Clinical Trial Evaluation 064)

<http://ClinicalTrials.gov/show/NCT01783938>

Study 346:

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma

<http://ClinicalTrials.gov/show/NCT01696045>

Study 347:

A Study of Intratumoral CAVATAK in Patients With Stage IIIC and Stage IV Malignant Melanoma

<http://ClinicalTrials.gov/show/NCT01227551>

Study 348:

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

<http://ClinicalTrials.gov/show/NCT01489059>

Study 349:

LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma

<http://ClinicalTrials.gov/show/NCT01820364>

Study 350:

Trial of pIL-12 Electroporation Malignant Melanoma

<http://ClinicalTrials.gov/show/NCT01502293>

Study 351:

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

<http://ClinicalTrials.gov/show/NCT01586195>

Study 352:

A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas

<http://ClinicalTrials.gov/show/NCT01815840>

Study 353:

Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma

<http://ClinicalTrials.gov/show/NCT01650090>

Study 354:

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

<http://ClinicalTrials.gov/show/NCT01440088>

Study 355:

A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

<http://ClinicalTrials.gov/show/NCT00210665>

Study 356:

A Safety Study of SGN-CD19A for B-Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01786135>

Study 357:

A Safety Study of SGN-CD19A for Leukemia and Lymphoma

<http://ClinicalTrials.gov/show/NCT01786096>

Study 358:

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

<http://ClinicalTrials.gov/show/NCT01843374>

Study 359:

A Study of Vismodegib With Surgery in Patients With Previously Untreated Basal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01898598>

Study 360:

Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation

<http://ClinicalTrials.gov/show/NCT01574716>

Study 361:

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

<http://ClinicalTrials.gov/show/NCT00752206>

Study 362:

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

<http://ClinicalTrials.gov/show/NCT01505608>

Study 363:

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

<http://ClinicalTrials.gov/show/NCT01483820>

Study 364:

Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC

<http://ClinicalTrials.gov/show/NCT01437605>

Study 365:

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

<http://ClinicalTrials.gov/show/NCT01176461>

Study 366:

SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

<http://ClinicalTrials.gov/show/NCT01261312>

Study 367:

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

<http://ClinicalTrials.gov/show/NCT01101581>

Study 368:

Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma

<http://ClinicalTrials.gov/show/NCT01712490>

Study 369:

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

<http://ClinicalTrials.gov/show/NCT01295710>

Study 370:

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

<http://ClinicalTrials.gov/show/NCT01777152>

Study 371:

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

<http://ClinicalTrials.gov/show/NCT01611090>

Study 372:

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

<http://ClinicalTrials.gov/show/NCT00601003>

Study 373:

Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

<http://ClinicalTrials.gov/show/NCT01586260>

Study 374:

Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma

<http://ClinicalTrials.gov/show/NCT01496807>

Study 375:

Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study

<http://ClinicalTrials.gov/show/NCT01760499>

Study 376:

Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

<http://ClinicalTrials.gov/show/NCT01460160>

Study 377:

A Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

<http://ClinicalTrials.gov/show/NCT01732913>

Study 378:

Ofatumumab Maintenance Treatment vs. No Further Treatment in Relapsed CLL Responding to Induction Therapy

<http://ClinicalTrials.gov/show/NCT01039376>

Study 379:

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

<http://ClinicalTrials.gov/show/NCT01476787>

Study 380:

Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

<http://ClinicalTrials.gov/show/NCT01200589>

Study 381:

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

<http://ClinicalTrials.gov/show/NCT00790036>

Study 382:

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

<http://ClinicalTrials.gov/show/NCT00774345>

Study 383:

Phase II Phosphatidylinositol 3-Kinase (PI3K) Inhibitor in Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (NHL)

<http://ClinicalTrials.gov/show/NCT01660451>

Study 384:

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01482962>

Study 385:

Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML—CP (Chronic Myelogenous Leukemia—Chronic Phase)

<http://ClinicalTrials.gov/show/NCT00718263>

Study 386:

A Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

<http://ClinicalTrials.gov/show/NCT01732926>

Study 387:

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

<http://ClinicalTrials.gov/show/NCT01321541>

Study 388:

Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5

<http://ClinicalTrials.gov/show/NCT01744665>

Study 389:

A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

<http://ClinicalTrials.gov/show/NCT01287741>

Study 390:

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

<http://ClinicalTrials.gov/show/NCT01421667>

Study 391:

Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

<http://ClinicalTrials.gov/show/NCT01510184>

Study 392:

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia

<http://ClinicalTrials.gov/show/NCT01696084>

Study 393:

A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma

<http://ClinicalTrials.gov/show/NCT01691898>

Study 394:

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNF α) Agents.

<http://ClinicalTrials.gov/show/NCT01350804>

Study 395:

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

<http://ClinicalTrials.gov/show/NCT01546038>

Study 396:

CNDO-109-AANK for AML in First Complete Remission (CR1)

<http://ClinicalTrials.gov/show/NCT01520558>

Study 397:

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

<http://ClinicalTrials.gov/show/NCT01390337>

Study 398:

A Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01578499>

Study 399:

A Phase 2 Trial of East Indian Sandalwood Oil in the Treatment of Common Warts (Verruca Vulgaris)

<http://ClinicalTrials.gov/show/NCT01286441>

Study 400:

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

<http://ClinicalTrials.gov/show/NCT01728805>

Study 401:

A Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

<http://ClinicalTrials.gov/show/NCT01659021>

Study 402:

Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older

<http://ClinicalTrials.gov/show/NCT01814826>

Study 403:

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01871727>

Study 404:

A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens: 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age

<http://ClinicalTrials.gov/show/NCT01358734>

Study 405:

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

<http://ClinicalTrials.gov/show/NCT01403636>

Study 406:

Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649 AM3)

<http://ClinicalTrials.gov/show/NCT01451437>

Study 407:

Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML

<http://ClinicalTrials.gov/show/NCT01883362>

Study 408:

KW 0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

<http://ClinicalTrials.gov/show/NCT01626664>

Study 409:

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

<http://ClinicalTrials.gov/show/NCT01294579>

Study 410:

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

<http://ClinicalTrials.gov/show/NCT01736683>

Study 411:

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

<http://ClinicalTrials.gov/show/NCT01564784>

Study 412:

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

<http://ClinicalTrials.gov/show/NCT01569295>

Study 413:

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

<http://ClinicalTrials.gov/show/NCT01303796>

Study 414:

Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma

<http://ClinicalTrials.gov/show/NCT01253148>

Study 415:

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease

<http://ClinicalTrials.gov/show/NCT01714726>

Study 416:

Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy

<http://ClinicalTrials.gov/show/NCT01626352>

Study 417:

A Moderate to Severe Rheumatoid Arthritis Study

<http://ClinicalTrials.gov/show/NCT01721044>

Study 418:

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

<http://ClinicalTrials.gov/show/NCT01776723>

Study 419:

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

<http://ClinicalTrials.gov/show/NCT01702064>

Study 420:

Phase 1/2 Study of Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

<http://ClinicalTrials.gov/show/NCT00831766>

Study 421:

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

<http://ClinicalTrials.gov/show/NCT00981799>

Study 422:

Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

<http://ClinicalTrials.gov/show/NCT01496976>

Study 423:

Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

<http://ClinicalTrials.gov/show/NCT01497496>

Study 424:

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

<http://ClinicalTrials.gov/show/NCT01643850>

Study 425:

Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

<http://ClinicalTrials.gov/show/NCT00840931>

Study 426:

Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

<http://ClinicalTrials.gov/show/NCT01772953>

Study 427:

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

<http://ClinicalTrials.gov/show/NCT01534078>

Study 428:

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

<http://ClinicalTrials.gov/show/NCT01759056>

Study 429:

Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis

<http://ClinicalTrials.gov/show/NCT01686152>

Study 430:

A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis

<http://ClinicalTrials.gov/show/NCT01742663>

Study 431:

Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

<http://ClinicalTrials.gov/show/NCT01873703>

Study 432:

Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis

<http://ClinicalTrials.gov/show/NCT01788007>

Study 433:

Efficacy and Safety Phase II Dose-ranging Study of SR-T100 to Treat Actinic Keratosis

<http://ClinicalTrials.gov/show/NCT01516515>

Study 434:

Birinapant With 5-azacitidine in MDS Subjects Who Relapsed or Are Refractory to 5-azacitidine Therapy

<http://ClinicalTrials.gov/show/NCT01828346>

Study 435:

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

<http://ClinicalTrials.gov/show/NCT01152346>

Study 436:

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

<http://ClinicalTrials.gov/show/NCT01713946>

Study 437:

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

<http://ClinicalTrials.gov/show/NCT01872078>

Study 438:

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

<http://ClinicalTrials.gov/show/NCT01496495>

Study 439:

Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia

<http://ClinicalTrials.gov/show/NCT01286038>

Study 440:

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

<http://ClinicalTrials.gov/show/NCT01822691>

Diabetes

(76 clinical trials recruiting)

Study 1:

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01541215>

Study 2:

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01720446>

Study 3:

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

<http://ClinicalTrials.gov/show/NCT01676116>

Study 4:

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily

<http://ClinicalTrials.gov/show/NCT01814137>

Study 5:

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01204775>

Study 6:

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01646320>

Study 7:

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01619059>

Study 8:

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01606007>

Study 9:

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

<http://ClinicalTrials.gov/show/NCT01394952>

Study 10:

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01719003>

Study 11:

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01778049>

Study 12:

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01734785>

Study 13:

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

<http://ClinicalTrials.gov/show/NCT01649297>

Study 14:

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

<http://ClinicalTrials.gov/show/NCT01434186>

Study 15:

Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

<http://ClinicalTrials.gov/show/NCT01841697>

Study 16:

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01144338>

Study 17:

A Study of the Safety and Efficacy of MK-3102 in ≥ 18 and < 45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028 AM1)

<http://ClinicalTrials.gov/show/NCT01814748>

Study 18:

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

<http://ClinicalTrials.gov/show/NCT01809327>

Study 19:

Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT00957268>

Study 20:

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01673178>

Study 21:

Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01885260>

Study 22:

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)

<http://ClinicalTrials.gov/show/NCT01682759>

Study 23:

Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis

<http://ClinicalTrials.gov/show/NCT01571297>

Study 24:

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonyleurea Therapy (AWARD-8)

<http://ClinicalTrials.gov/show/NCT01769378>

Study 25:

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01455857>

Study 26:

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01455870>

Study 27:

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

<http://ClinicalTrials.gov/show/NCT01455896>

Study 28:

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01481116>

Study 29:

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

<http://ClinicalTrials.gov/show/NCT01609582>

Study 30:

Comparison of TAK-875 With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01834274>

Study 31:

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

<http://ClinicalTrials.gov/show/NCT01621178>

Study 32:

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

<http://ClinicalTrials.gov/show/NCT01785771>

Study 33:

Evaluate Safety of T/I on Diabetic Subjects With Mild Obstructive Pulmonary Disease

<http://ClinicalTrials.gov/show/NCT00642616>

Study 34:

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

<http://ClinicalTrials.gov/show/NCT01703208>

Study 35:

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289 AM2)

<http://ClinicalTrials.gov/show/NCT01760447>

Study 36:

A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296 AM1)

<http://ClinicalTrials.gov/show/NCT01557504>

Study 37:

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01843127>

Study 38:

A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)

<http://ClinicalTrials.gov/show/NCT01678820>

Study 39:

A Study to Assess the Safety and Efficacy of MK-3102 in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011 AM2)

<http://ClinicalTrials.gov/show/NCT01717313>

Study 40:

Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM4)

<http://ClinicalTrials.gov/show/NCT01704261>

Study 41:

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024 AM4)

<http://ClinicalTrials.gov/show/NCT01755156>

Study 42:

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01819129>

Study 43:

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

<http://ClinicalTrials.gov/show/NCT01619332>

Study 44:

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

<http://ClinicalTrials.gov/show/NCT01798706>

Study 45:

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

<http://ClinicalTrials.gov/show/NCT01730534>

Study 46:

Multiple Ascending Dose Study in Subjects With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01856881>

Study 47:

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin

<http://ClinicalTrials.gov/show/NCT01929863>

Study 48:

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

<http://ClinicalTrials.gov/show/NCT01768559>

Study 49:

A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01790438>

Study 50:

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170 AM1)

<http://ClinicalTrials.gov/show/NCT01472367>

Study 51:

A Study to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)

<http://ClinicalTrials.gov/show/NCT01863667>

Study 52:

A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019 AM3)

<http://ClinicalTrials.gov/show/NCT01698775>

Study 53:

Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01835730>

Study 54:

A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

<http://ClinicalTrials.gov/show/NCT01712061>

Study 55:

Statins in Children With Type 1 Diabetes and Hypercholesterolemia

<http://ClinicalTrials.gov/show/NCT01236365>

Study 56:

A Study of How LY2605541 and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics

<http://ClinicalTrials.gov/show/NCT01925989>

Study 57:

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

<http://ClinicalTrials.gov/show/NCT01874431>

Study 58:

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

<http://ClinicalTrials.gov/show/NCT01752985>

Study 59:

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01549964>

Study 60:

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01794143>

Study 61:

Determination of Safety, Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of Single & Multiple Doses of P11187

<http://ClinicalTrials.gov/show/NCT01874366>

Study 62:

Insulin Resistance Intervention After Stroke Trial

<http://ClinicalTrials.gov/show/NCT00091949>

Study 63:

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

<http://ClinicalTrials.gov/show/NCT01807221>

Study 64:

A Study in Patients With Diabetic Kidney Disease

<http://ClinicalTrials.gov/show/NCT01113801>

Study 65:

Study Of Diabetic Nephropathy With Atrasentan

<http://ClinicalTrials.gov/show/NCT01858532>

Study 66:

Evaluation of CureXcell™ in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes

<http://ClinicalTrials.gov/show/NCT01421966>

Study 67:

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

<http://ClinicalTrials.gov/show/NCT01849965>

Study 68:

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

<http://ClinicalTrials.gov/show/NCT01830348>

Study 69:

A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers

<http://ClinicalTrials.gov/show/NCT01824407>

Study 70:

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

<http://ClinicalTrials.gov/show/NCT01147250>

Study 71:

A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

<http://ClinicalTrials.gov/show/NCT01683409>

Study 72:

Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

<http://ClinicalTrials.gov/show/NCT01455415>

Study 73:

A Study to Evaluate the Efficacy and Safety of a Single Application of QUTENZA Compared to That of Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

<http://ClinicalTrials.gov/show/NCT01533428>

Study 74:

A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE)

<http://ClinicalTrials.gov/show/NCT01490879>

Study 75:

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

<http://ClinicalTrials.gov/show/NCT01601236>

Study 76:

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

<http://ClinicalTrials.gov/show/NCT01476449>

Heart Disease (47 clinical trials recruiting)

Study 1:

Intracardiac Cryoablation for AtrioVentricular Nodal Reentrant Tachycardia

<http://ClinicalTrials.gov/show/NCT01426425>

Study 2:

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

<http://ClinicalTrials.gov/show/NCT01475825>

Study 3:

Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

<http://ClinicalTrials.gov/show/NCT01508910>

Study 4:

A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System

<http://ClinicalTrials.gov/show/NCT01614652>

Study 5:

Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia

<http://ClinicalTrials.gov/show/NCT01556022>

Study 6:

Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement

<http://ClinicalTrials.gov/show/NCT01531374>

Study 7:

A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

<http://ClinicalTrials.gov/show/NCT01643330>

Study 8:

Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter

<http://ClinicalTrials.gov/show/NCT01253200>

Study 9:

ST Monitoring to Detect Acute Coronary Syndrome Events in Implantable Cardioverter Defibrillator Patients

<http://ClinicalTrials.gov/show/NCT01424722>

Study 10:

The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)

<http://ClinicalTrials.gov/show/NCT01665053>

Study 11:

A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

<http://ClinicalTrials.gov/show/NCT01618669>

Study 12:

Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727) (ODYSSEY Outcomes)

<http://ClinicalTrials.gov/show/NCT01663402>

Study 13:

COSMIC-HF—Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

<http://ClinicalTrials.gov/show/NCT01786512>

Study 14:

Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure

<http://ClinicalTrials.gov/show/NCT01661634>

Study 15:

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

<http://ClinicalTrials.gov/show/NCT01674647>

Study 16:

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

<http://ClinicalTrials.gov/show/NCT01730534>

Study 17:

AngelMed for Early Recognition and Treatment of STEMI

<http://ClinicalTrials.gov/show/NCT00781118>

Study 18:

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

<http://ClinicalTrials.gov/show/NCT01147250>

Study 19:

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure

<http://ClinicalTrials.gov/show/NCT00853658>

Study 20:

INcrease OfVAgal TonE in CHF

<http://ClinicalTrials.gov/show/NCT01303718>

Study 21:

A Study Exploring Two Strategies of Rivaroxaban and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

<http://ClinicalTrials.gov/show/NCT01830543>

Study 22:

An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

<http://ClinicalTrials.gov/show/NCT01670981>

Study 23:

Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

<http://ClinicalTrials.gov/show/NCT01522417>

Study 24:

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure

<http://ClinicalTrials.gov/show/NCT01643590>

Study 25:

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

<http://ClinicalTrials.gov/show/NCT01732822>

Study 26:

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

<http://ClinicalTrials.gov/show/NCT01327846>

Study 27:

AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction

<http://ClinicalTrials.gov/show/NCT01495364>

Study 28:

The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves

<http://ClinicalTrials.gov/show/NCT01314313>

Study 29:

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

<http://ClinicalTrials.gov/show/NCT01483183>

Study 30:

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

<http://ClinicalTrials.gov/show/NCT01522651>

Study 31:

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

<http://ClinicalTrials.gov/show/NCT01807221>

Study 32:

Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With Acute Coronary Events

<http://ClinicalTrials.gov/show/NCT01572909>

Study 33:

Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure

<http://ClinicalTrials.gov/show/NCT01112579>

Study 34:

MultiPoint Pacing IDE Study

<http://ClinicalTrials.gov/show/NCT01786993>

Study 35:

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System—Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

<http://ClinicalTrials.gov/show/NCT01456000>

Study 36:

nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

<http://ClinicalTrials.gov/show/NCT01824394>

Study 37:

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

<http://ClinicalTrials.gov/show/NCT01639495>

Study 38:

Vest Prevention of Early Sudden Death Trial and VEST Registry

<http://ClinicalTrials.gov/show/NCT01446965>

Study 39:

Insulin Resistance Intervention After Stroke Trial

<http://ClinicalTrials.gov/show/NCT00091949>

Study 40:

Regadenoson to Achieve Maximal Hyperemia for Fractional Flow Reserve in the Catheterization Lab

<http://ClinicalTrials.gov/show/NCT01161121>

Study 41:

Impact and Time Course of Colchicine Therapy on C-reactive Protein Elevation in Chronic Atrial Fibrillation and Post AF Ablation

<http://ClinicalTrials.gov/show/NCT01755949>

Study 42:

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

<http://ClinicalTrials.gov/show/NCT01776424>

Study 43:

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

<http://ClinicalTrials.gov/show/NCT01777165>

Study 44:

Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

<http://ClinicalTrials.gov/show/NCT01528709>

Study 45:

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

<http://ClinicalTrials.gov/show/NCT01101035>

Study 46:

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

<http://ClinicalTrials.gov/show/NCT01813422>

Study 47:

Contrast Media Reduction and Removal in Patients With CKD (PRESERV)

<http://ClinicalTrials.gov/show/NCT01168024>

Mental Illness

(98 clinical trials recruiting)

Study 1:

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

<http://ClinicalTrials.gov/show/NCT01727726>

Study 2:

A Study of Three Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

<http://ClinicalTrials.gov/show/NCT01862640>

Study 3:

Relapse Prevention Study in Patients With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01291511>

Study 4:

AR08 for Treatment of ADHD in Children

<http://ClinicalTrials.gov/show/NCT01876719>

Study 5:

Safety & Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

<http://ClinicalTrials.gov/show/NCT01416441>

Study 6:

Adult Attention Deficit Hyperactivity Disorder

<http://ClinicalTrials.gov/show/NCT01692782>

Study 7:

A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

<http://ClinicalTrials.gov/show/NCT01458340>

Study 8:

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

<http://ClinicalTrials.gov/show/NCT01405053>

Study 9:

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

<http://ClinicalTrials.gov/show/NCT01418352>

Study 10:

NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

<http://ClinicalTrials.gov/show/NCT01835548>

Study 11:

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder

<http://ClinicalTrials.gov/show/NCT01904773>

Study 12:

A Trial of CM-AT in Children With Autism—Open Label Extension Study

<http://ClinicalTrials.gov/show/NCT00912691>

Study 13:

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

<http://ClinicalTrials.gov/show/NCT00550238>

Study 14:

A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

<http://ClinicalTrials.gov/show/NCT00637494>

Study 15:

Nutritional Intervention in Children With Autism Using Whey Protein (Immunocal): Impact on Core Areas of Behavior

<http://ClinicalTrials.gov/show/NCT01366859>

Study 16:

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

<http://ClinicalTrials.gov/show/NCT01739348>

Study 17:

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

<http://ClinicalTrials.gov/show/NCT01741194>

Study 18:

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01663532>

Study 19:

Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01683058>

Study 20:

An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

<http://ClinicalTrials.gov/show/NCT01715805>

Study 21:

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01735630>

Study 22:

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01469377>

Study 23:

Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression

<http://ClinicalTrials.gov/show/NCT01396447>

Study 24:

Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01670279>

Study 25:

Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder

<http://ClinicalTrials.gov/show/NCT01467700>

Study 26:

Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder

<http://ClinicalTrials.gov/show/NCT01766401>

Study 27:

A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01224106>

Study 28:

A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01767311>

Study 29:

Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder in Adult Patients

<http://ClinicalTrials.gov/show/NCT01467713>

Study 30:

A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01529515>

Study 31:

Open Label Extension in Adults With Binge Eating Disorder (BED)

<http://ClinicalTrials.gov/show/NCT01657019>

Study 32:

Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01515423>

Study 33:

A Long-Term Safety Extension Study of Studies ABE4869g And ABE4955g in Patients With Mild To Moderate Alzheimer's Disease Treated With Crenezumab

<http://ClinicalTrials.gov/show/NCT01723826>

Study 34:

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01689233>

Study 35:

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

<http://ClinicalTrials.gov/show/NCT01584440>

Study 36:

Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01364649>

Study 37:

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01436149>

Study 38:

MAYfLOWeR RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

<http://ClinicalTrials.gov/show/NCT01677754>

Study 39:

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

<http://ClinicalTrials.gov/show/NCT01361555>

Study 40:

SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01435759>

Study 41:

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

<http://ClinicalTrials.gov/show/NCT01900665>

Study 42:

Study Evaluating The Safety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

<http://ClinicalTrials.gov/show/NCT01712074>

Study 43:

ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment

<http://ClinicalTrials.gov/show/NCT01457677>

Study 44:

Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder

<http://ClinicalTrials.gov/show/NCT01677182>

Study 45:

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01397786>

Study 46:

Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01878292>

Study 47:

Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder

<http://ClinicalTrials.gov/show/NCT01607658>

Study 48:

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01436162>

Study 49:

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01677572>

Study 50:

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

<http://ClinicalTrials.gov/show/NCT01371708>

Study 51:

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

<http://ClinicalTrials.gov/show/NCT01714713>

Study 52:

A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

<http://ClinicalTrials.gov/show/NCT01371721>

Study 53:

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

<http://ClinicalTrials.gov/show/NCT01371734>

Study 54:

Induction, STabilization, Adherence and Retention Trial (ISTART) of OX219 Buprenorphine/Naloxone

<http://ClinicalTrials.gov/show/NCT01908842>

Study 55:

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

<http://ClinicalTrials.gov/show/NCT01372150>

Study 56:

Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01564862>

Study 57:

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

<http://ClinicalTrials.gov/show/NCT01521663>

Study 58:

A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25308)

<http://ClinicalTrials.gov/show/NCT01192880>

Study 59:

Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)

<http://ClinicalTrials.gov/show/NCT01724112>

Study 60:

Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

<http://ClinicalTrials.gov/show/NCT01844115>

Study 61:

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

<http://ClinicalTrials.gov/show/NCT01429116>

Study 62:

Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

<http://ClinicalTrials.gov/show/NCT01396421>

Study 63:

Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems

<http://ClinicalTrials.gov/show/NCT01743235>

Study 64:

A Study to Evaluate the Efficacy and Safety of ALKS 9072 in Subjects With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01469039>

Study 65:

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01689246>

Study 66:

Study to Assess OX219 (Buprenorphine/Naloxone) for the Induction of Treatment of Opioid Dependence

<http://ClinicalTrials.gov/show/NCT01848054>

Study 67:

Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01149655>

Study 68:

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)

<http://ClinicalTrials.gov/show/NCT01235559>

Study 69:

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder

<http://ClinicalTrials.gov/show/NCT01629966>

Study 70:

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

<http://ClinicalTrials.gov/show/NCT01626378>

Study 71:

Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia

<http://ClinicalTrials.gov/show/NCT01393613>

Study 72:

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

<http://ClinicalTrials.gov/show/NCT01235520>

Study 73:

The Safety and Efficacy of AF-219 in Female Subjects With Interstitial Cystitis/Bladder Pain Syndrome

<http://ClinicalTrials.gov/show/NCT01569438>

Study 74:

A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

<http://ClinicalTrials.gov/show/NCT01678755>

Study 75:

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

<http://ClinicalTrials.gov/show/NCT01626456>

Study 76:

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive-Compulsive Disorder

<http://ClinicalTrials.gov/show/NCT01674361>

Study 77:

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01492374>

Study 78:

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

<http://ClinicalTrials.gov/show/NCT01518374>

Study 79:

Lurasidone Low-Dose - High-Dose Study

<http://ClinicalTrials.gov/show/NCT01821378>

Study 80:

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy

<http://ClinicalTrials.gov/show/NCT01624480>

Study 81:

Efficacy, Safety and Dose-Response Study of Lofexidine in the Treatment of Opioid Withdrawal Followed by Open-Label Lofexidine Treatment

<http://ClinicalTrials.gov/show/NCT01863186>

Study 82:

Safety and Efficacy Study of Deep Transcranial Magnetic Stimulation in Bipolar Depression

<http://ClinicalTrials.gov/show/NCT01566591>

Study 83:

ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01608061>

Study 84:

Cariprazine Relative to Placebo in the Prevention of Relapse of Symptoms in Patients With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01412060>

Study 85:

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01668797>

Study 86:

Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

<http://ClinicalTrials.gov/show/NCT01837797>

Study 87:

Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

<http://ClinicalTrials.gov/show/NCT01908010>

Study 88:

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

<http://ClinicalTrials.gov/show/NCT01498120>

Study 89:

A Study of LY3002813 in Participants With Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01837641>

Study 90:

A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

<http://ClinicalTrials.gov/show/NCT01537042>

Study 91:

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

<http://ClinicalTrials.gov/show/NCT01714661>

Study 92:

Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects

<http://ClinicalTrials.gov/show/NCT01887366>

Study 93:

A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients

<http://ClinicalTrials.gov/show/NCT01730768>

Study 94:

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects Receiving Chronic Stable Atypical Antipsychotic Therapy

<http://ClinicalTrials.gov/show/NCT01716975>

Study 95:

Study to Evaluate Dietary Supplementation With a Version of Anatabloc® in Subjects With Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01669876>

Study 96:

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

<http://ClinicalTrials.gov/show/NCT01495793>

Study 97:

7-Keto DHEA for the Treatment of PTSD

<http://ClinicalTrials.gov/show/NCT01861847>

Study 98:

Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis

<http://ClinicalTrials.gov/show/NCT01848327>

Stroke

(16 clinical trials recruiting)

Study 1:

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

<http://ClinicalTrials.gov/show/NCT01208233>

Study 2:

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

<http://ClinicalTrials.gov/show/NCT01273337>

Study 3:

Study to Examine the Effects of MultiStem in Ischemic Stroke

<http://ClinicalTrials.gov/show/NCT01436487>

Study 4:

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

<http://ClinicalTrials.gov/show/NCT01221246>

Study 5:

POC in Patients With Ischaemic Stroke

<http://ClinicalTrials.gov/show/NCT01808261>

Study 6:

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

<http://ClinicalTrials.gov/show/NCT00826059>

Study 7:

Insulin Resistance Intervention After Stroke Trial

<http://ClinicalTrials.gov/show/NCT00091949>

Study 8:

BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity

<http://ClinicalTrials.gov/show/NCT01575054>

Study 9:

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

<http://ClinicalTrials.gov/show/NCT01730534>

Study 10:

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

<http://ClinicalTrials.gov/show/NCT01732822>

Study 11:

Dysport® Adult Lower Limb Spasticity Study

<http://ClinicalTrials.gov/show/NCT01249404>

Study 12:

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

<http://ClinicalTrials.gov/show/NCT01674647>

Study 13:

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

<http://ClinicalTrials.gov/show/NCT01776424>

Study 14:

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

<http://ClinicalTrials.gov/show/NCT01101035>

Study 15:

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

<http://ClinicalTrials.gov/show/NCT01327846>

Study 16:

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

<http://ClinicalTrials.gov/show/NCT01344447>



Pharmaceutical Research and Manufacturers of America
950 F Street, NW, Washington, DC 20004

www.phrma.org